Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 3.

Participants in the San Antonio Breast Cancer Symposium today heard evidence that exemestane may be an effective alternative to anastrozole in adjuvant aromatase inhibitor therapy for early breast cancer, in a study titled: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer.

For more information from SABCS 2010, please click here: SABCS 2010.

Produced by The Doctor’s Channel